Example: barber

Extravasation Management

Found 10 free book(s)
DRUG NAME: Oxaliplatin

DRUG NAME: Oxaliplatin

www.bccancer.bc.ca

Management of extravasation: Extravasation of oxaliplatin may sometimes cause severe local inflammation and potentially tissue necrosis. 31-36. The optimal non-pharmacological management of oxaliplatin extravasation is unclear. However, it has been suggested that warm compresses may be

  Management, Extravasation

BC Cancer Protocol Summary for Treatment of Lymphoma …

BC Cancer Protocol Summary for Treatment of Lymphoma …

www.bccancer.bc.ca

IV administration allows for better management of reactions by slowing or stopping the infusion. ‡During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative ... Extravasation: DOXOrubicin and vinCRIStine cause pain and tissue necrosis if extravasated. Refer to BC Cancer Extravasation Guidelines. 4.

  Management, Extravasation

Occlusion Management Guideline for Central Venous Access ...

Occlusion Management Guideline for Central Venous Access ...

improvepicc.com

treatment, yet there is a lack of standard practices for CVAD occlusion management ... vessel wall and with minimal risk of extravasation and chemical phlebitis. 1- 3 CVADs also provide an access for blood sampling.2 ,6 7 The four main types of …

  Management, Occlusion, Extravasation, Occlusion management

ENDOCRINE TEST PROTOCOLS - BC Children’s

ENDOCRINE TEST PROTOCOLS - BC Children’s

www.bcchildrens.ca

IN CASE OF EXTRAVASATION, page the staff endocrinologist STAT. Order a 1500-unit vial of hyaluronidase to the MIF STAT. Initiate the C&W Policy & Procedure . Prevention and Management of Infiltration and Extravasation - Guidelines for Antidote Administration. SPECIMENS: TIME AMOUNT TEST . 0 min baseline* 1 mL red top GH . 30 min post-arginine

  Management, Extravasation

DRUG NAME: Bendamustine - BC Cancer

DRUG NAME: Bendamustine - BC Cancer

www.bccancer.bc.ca

extravasation hazard: irritant. 9,10. catheter/ infusion site pain (5-7%) chills (6-14%) fatigue (9-64%, severe 1-14%) injection site reactions, including erythema, phlebitis, pruritus, marked swelling, and pain (2-7%) ... the management of tumour lysis syndrome; however, the concomitant use of bendamustine and allopurinol may ...

  Management, Extravasation

DRUG NAME: Paclitaxel

DRUG NAME: Paclitaxel

www.bccancer.bc.ca

Prevention and Management of Extravasation of Chemotherapy. Hypersensitivity reactions. typically occur within the first 10 minutes of the first two cycles. 2,24. Reactions are caused by either a histamine release in response to polyoxyl 35 …

  Management, Extravasation

Diagnosis and management of acute lower gastrointestinal ...

Diagnosis and management of acute lower gastrointestinal ...

gut.bmj.com

Oct 26, 2018 · of cases.6 If extravasation of contrast is shown on CTA, formal, invasive angiography with the option of mesenteric embolisa-tion can be undertaken, although in practice embolisation is used in <1% of cases.6 Emergency laparotomy for bleeding is very uncommon.5 6the most commonOverall, intervention is red blood cell (RBC) transfusion.4

  Management, Extravasation

Extravasation Management Reference Sheet

Extravasation Management Reference Sheet

www.nacns.org

Extravasation Management Reference Sheet Medication Thermal Therapy Antidote Dose Treatment Amino acids (4.25%) Heat Hyaluronidase 150 units Give via 5-10 SQ or TD injections into area of extravasation Aminophylline Heat Hyaluronidase 150 units Give via 5-10 SQ or TD injections into area of extravasation Calcium chloride (>10%)

  Management, Extravasation management, Extravasation

Version No.: &lt;no&gt; ; Effective From: &lt;date&gt; Page 1 of 26 ...

Version No.: <no> ; Effective From: <date> Page 1 of 26 ...

www.health.qld.gov.au

This guideline has been developed as part of the I-Care intervention bundle for the management of intravascular devices (IVDs). This g uideline provides recommendations regarding best practice for the use and management of invasive devices based on current evidence for the prevention and control of healthcare associated infection (HAI). 2. Scope

  Management

Peripheral I.V. Infiltrations

Peripheral I.V. Infiltrations

elpaso.ttuhsc.edu

Management Stop the infusion Disconnect the iv tubing, attach a syringe and aspirate any residual drug from the site Determine if infusate is a vesicant or irritant Remove the iv if it is not a vesicant Leave the iv in situ if it is a vesicant Describe the site using the INS classification scale Elevate the affected extremity ...

  Management

Similar queries